In-vitro activity of Sch 34343 against nosocomial pathogens: methicillin-resistant staphylococci, gentamicin-susceptible and -resistant Streptococcus faecalis, Clostridium difficile and Bacteroides fragilis
The in-vitro activity of Sch 34343, a new β -lactam antimicrobial, was studied in vitro by quantitative broth dilution methods. It was found to have good antibacterial activity against four emerging problem pathogens: methicillin-resistant Staphylococcus aureus. Streptococcus faecalis isolates showing high level resistance to gentamicin (and other aminoglycosides), Clostridhtm difficile (the cause of pseudomembraneous colitis), and Bacteroides fragilis . On the basis of these promising results, Sch 34343 merits further in-vitro and in-vivo study to define its potential usefulness in treatment of infections with these pathogens in humans.